Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ciltacabtagene autoleucel

- PMLiVE

EU fast-tracks review of Pfizer/BioNTech COVID-19 vaccine

CHMP meeting scheduled for 21 December

- PMLiVE

J&J trims the size of its phase 3 COVID-19 vaccine trial

Company cuts size of participant population from 60,000 to 40,000

- PMLiVE

EMA launches rolling review of J&J’s COVID-19 vaccine

Vaccine entered phase 3 testing in September

EU flag

EU buys 160 million doses of Moderna’s COVID-19 vaccine

Deal follows positive data readout last week

Sanofi reception

Sanofi’s quadrivalent flu vaccine Supemtek scores EU approval

Company expects first EU launches in 2022/2023 flu season

- PMLiVE

EU secures 405 million doses of CureVac’s COVID-19 vaccine

CureVac revealed early stage data for its vaccine earlier this month

EU flag

EU agrees on supply deal for 200 million doses of Pfizer, BioNTech’s COVID-19 vaccine

European Commission will have an option to request another 100 million doses

- PMLiVE

Both AZ and J&J set to resume US COVID-19 vaccine trials

Both companies paused their trials after separate participant illness events

- PMLiVE

J&J halts COVID-19 vaccine study after unexplained participant illness

Company convened data and safety monitoring board to review event

- PMLiVE

EU announces agreement with Gilead for remdesivir supply

Drug was granted conditional marketing authorisation in the EU in July

- PMLiVE

J&J signs deal with EU for 200 million COVID-19 vaccine doses

EU member states will have an option to secure 200 million additional doses

- PMLiVE

Phase 1/2a results for J&J’s COVID-19 vaccine show early promise

Vaccine produced neutralising antibodies in 98% of participants

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links